Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H12N2O8.Ca.2Na.2H2O |
| Molecular Weight | 410.299 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
InChI
InChIKey=JCQNARRMQCMKAN-UHFFFAOYSA-J
InChI=1S/C10H16N2O8.Ca.2Na.2H2O/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;;2*1H2/q;+2;2*+1;;/p-4
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H14N2O8 |
| Molecular Weight | 290.2268 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acidCurator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Sources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acid
Curator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation.
Originator
Sources: https://www.researchgate.net/publication/321552574_Ferdinand_Munz_EDTA_and_40_years_of_inventionshttps://www.google.com/patents/US2130505
Curator's Comment: Edetic acid was synthesized by Ferdinand Munz.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: divalent and trivalent metals |
|||
Target ID: CHEMBL2364029 |
18.3 null [pKd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Calcium disodium versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date1953 |
|||
| Curative | Calcium Disodium Versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date1953 |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
51 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096624 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
EDETATE CALCIUM DISODIUM serum | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60 min |
unknown, unknown |
EDETATE CALCIUM DISODIUM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Sources: |
unhealthy, 1-8 |
Disc. AE: Acute renal failure... Other AEs: Nephrotoxicity... AEs leading to discontinuation/dose reduction: Acute renal failure (3%) Other AEs:Nephrotoxicity (mild, 13%) Sources: |
160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: |
unhealthy, 49 |
Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: |
400 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: |
unhealthy, 58 |
Disc. AE: Restlessness, Hypocalcemia... AEs leading to discontinuation/dose reduction: Restlessness Sources: Hypocalcemia |
400 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: |
unhealthy, 58 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Acute renal failure | 3% Disc. AE |
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Sources: |
unhealthy, 1-8 |
| Nephrotoxicity | mild, 13% | 25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Sources: |
unhealthy, 1-8 |
| Hypocalcemia | Disc. AE | 160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: |
unhealthy, 49 |
| Hypocalcemia | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: |
unhealthy, 58 |
| Restlessness | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: |
unhealthy, 58 |
| Headache | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: |
unhealthy, 58 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lead mobilization study and the clearance of intravenous CaNa2EDTA in a patient with end-stage renal failure on hemodialysis. | 2012-01 |
|
| EDTA redistribution of lead and cadmium into the soft tissues in a human with a high lead burden - should DMSA always be used to follow EDTA in such cases? | 2011-06 |
|
| Chemical speciation used to assess [S,S']-ethylenediaminedisuccinic acid (EDDS) as a readily-biodegradable replacement for EDTA in radiochemical decontamination formulations. | 2001-04 |
|
| Cloning and biochemical characterization of BglC, a beta-glucosidase from the cellulolytic actinomycete Thermobifida fusca. | 2001-04 |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001-03-15 |
|
| Measurement of intact insulin-like growth factor-binding protein-3 in human plasma using a ligand immunofunctional assay. | 2001-03 |
|
| Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5. | 2001-03 |
|
| Adherence of Giardia lamblia trophozoites to Int-407 human intestinal cells. | 2001-03 |
|
| Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases. | 2001-03 |
|
| Kinetic modeling of liquid-phase adsorption of reactive dyes and metal ions on chitosan. | 2001-03 |
|
| Two new modes of smooth muscle myosin regulation by the interaction between the two regulatory light chains, and by the S2 domain. | 2001-03 |
|
| Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. | 2001-03 |
|
| Effect of collagenase inhibitors on corneal haze after PRK. | 2001-03 |
|
| Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. | 2001-02-17 |
|
| Characterization of a model compound for the lysine tyrosylquinone cofactor of lysyl oxidase. | 2001-02-16 |
|
| Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan). | 2001-02-15 |
|
| Influence of citrate and EDTA anticoagulants on plasma malondialdehyde concentrations estimated by high-performance liquid chromatography. | 2001-02-10 |
|
| Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. | 2001-02 |
|
| Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. | 2001-02 |
|
| Prolonged stability of endogenous cardiotrophin-1 in whole blood. | 2001-02 |
|
| Characterization of a protease responsible for truncated actin increase in neutrophils of patients with Behçet's disease. | 2001-02 |
|
| Microwave decalcification of human temporal bones. | 2001-02 |
|
| Binding sites for progastrin-derived peptides in colonic crypts. | 2001-02 |
|
| Estimation of glomerular filtration rate in cancer patients. | 2001-02 |
|
| Localization of estrogen receptor beta protein expression in adult human bone. | 2001-02 |
|
| Simultaneous determination of 226Ra and 210Pb in groundwater and soil samples by using the liquid scintillation counter-suspension gel method. | 2001-02 |
|
| Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. | 2001-02 |
|
| Determination of glomerular filtration rate per unit renal volume using computerized tomography: correlation with conventional measures of total and divided renal function. | 2001-02 |
|
| Environmental lead exposure and progressive renal insufficiency. | 2001-01-22 |
|
| Long-term preservation of chilled canine semen: effect of commercial and laboratory prepared extenders. | 2001-01-15 |
|
| The occurrence of internal (1 --> 5)-linked arabinofuranose and arabinopyranose residues in arabinogalactan side chains from soybean pectic substances. | 2001-01-15 |
|
| Determination of metal complexes of ethylenediaminetetraacetate in the presence of organic matter by high-performance liquid chromatography. | 2001-01-05 |
|
| Robustness of slope-intercept versus slope-only for measurement of glomerular filtration rate. | 2001-01 |
|
| Phagocytic response of bovine polymorphonuclear leukocytes to different incubation conditions and following exposure to some effectors of phagocytosis and different anticoagulants in vitro. | 2001-01 |
|
| Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. | 2001-01 |
|
| Differential inhibitory mechanism of Fe2+ and Fe3+ on contraction of ileal longitudinal smooth muscle. | 2001-01 |
|
| Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. | 2001-01 |
|
| Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats. | 2001-01 |
|
| Flow cytometric analysis of the human articular chondrocyte phenotype in vitro. | 2001-01 |
|
| Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. | 2001 |
|
| Hydroxyl radical footprinting of proteins using metal ion complexes. | 2001 |
|
| Artificial iron-dependent proteases. | 2001 |
|
| Evaluation of Er:YAG laser and EDTAC on dentin adhesion of six endodontic sealers. | 2001 |
|
| Attachment of human gingival fibroblasts to periodontally involved root surface following scaling and/or etching procedures: a scanning electron microscopy study. | 2001 |
|
| Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
| Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. | 2001 |
|
| Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. | 2001 |
|
| Chromosomal mapping, gene structure and characterization of the human and murine RAB27B gene. | 2001 |
|
| Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy. | 2001 |
|
| Effect of ethylenediaminetetraacetic acid (EDTA) on acute mercury poisoning of toad. | 1986 |
Sample Use Guides
hypercalcemia: adults: 50 mg/kg/day (up to 3 g/day) administered by slow IV infusion. Frequency and duration of administration are quite variable, and should be determined based on the patient's serum calcium. Five consecutive daily doses may be administered, followed by 2 days without medication, repeating these courses as necessary to a total of 15 doses.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:01 GMT 2025
by
admin
on
Mon Mar 31 17:46:01 GMT 2025
|
| Record UNII |
25IH6R4SGF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
||
|
CFR |
21 CFR 172.120
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
||
|
NCI_THESAURUS |
C360
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20217976
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
25IH6R4SGF
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
46245300
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
23411-34-9
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
1903
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB73104
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
1232006
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
DBSALT002785
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
100000136044
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
25IH6R4SGF
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200375
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
4757
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
6766-87-6
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
C334
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | |||
|
EDETATE CALCIUM DISODIUM
Created by
admin on Mon Mar 31 17:46:01 GMT 2025 , Edited by admin on Mon Mar 31 17:46:01 GMT 2025
|
PRIMARY | Description: A white or creamy white powder; almost odourless. Solubility: Soluble in 2 parts of water; very slightly soluble in ethanol (~750 g/l) TS; practically insoluble in in ether R. Category: Antidote, chelating agent for metals, mainly lead. Storage: Sodium calcium edetate should be kept in a tightly closed container. Additional information: Even in the absence of light, Sodium calcium edetate is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Sodium calcium edetate contains not less than 97.0% and not more than 102.0% of C10H12CaN2Na2O8, calculated with reference to the anhydrous substance. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|